Favezelimab/pembrolizumab is a fixed-dose combination of two monoclonal antibodies developed by Merck to treat various cancers.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.